Telesair

Executive Summary

Telesair is a Southern California-based medical device company dedicated to transforming respiratory care through innovative non-invasive ventilation and high-flow oxygen therapy solutions. Founded in 2018, the company has developed the Bonhawa High Flow Oxygen Therapy (HFOT) system, a portable device designed to bridge hospital and home care settings. By addressing the growing demand for home-based respiratory support, Telesair aims to improve patient outcomes and reduce healthcare costs. The company operates in the large and expanding respiratory market, driven by an aging population and rising prevalence of chronic respiratory diseases. While Telesair has not yet disclosed funding or valuation, its focus on portable, user-friendly technology positions it well for adoption in both institutional and home environments. With a clear product and a defined market need, Telesair is poised for growth, though it faces competition from established players such as Fisher & Paykel and ResMed. The company's success will hinge on regulatory clearances, commercial partnerships, and clinical evidence supporting its device's efficacy.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Bonhawa System70% success
• Q4 2026Strategic Distribution Partnership with a Major Hospital Network50% success
• Q2 2027Completion of a Pivotal Clinical Study Demonstrating Non-Inferiority to Standard HFOT60% success